| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V44463-1mg |
≥98% | ￥1190.00 |
货期：3-5天 | - | - | - | - |
|
V44463-5mg |
≥98% | ￥2990.00 |
货期：3-5天 | - | - | - | - |
|
V44463-10mg |
≥98% | ￥4790.00 |
货期：3-5天 | - | - | - | - |
|
V44463-25mg |
≥98% | ￥8630.00 |
货期：3-5天 | - | - | - | - |
|
V44463-50mg |
≥98% | ￥13800.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究： | Epaminurad (0-30 mg/kg, Orally, once a day for 3 consecutive days) shows uricosuric and urate-lowering effects[1]. Epaminurad (3-30 mg/kg, Orally, once) shows a good pharmacokinetic profile, increases the fractional excretion of urinary uric acid, and reduces plasma uric acid more effectively[1]. Pharmacokinetic Parameters of Epaminurad (UR-1102) in tufted capuchin monkeys[1]. |
||||||||||||||||||||
| 体内研究： | UR-1102 (0-12 μM) inhibits urate and PAH (p-aminohippuric acid) uptake by HEK293 cells transiently expressing URAT1, OAT1, or OAT3. | ||||||||||||||||||||
| 参考文献： | 1. Ahn SO, et al. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone. J Pharmacol Exp Ther. 2016 Apr;357(1):157-66. |
||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京